Skip to main content
TipRanks
Go Ultimate75% OFF

Newtopia (NEWU.H) AI Stock Analysis

10 Followers
TSE:NEWU.H

Newtopia

(TSXV:NEWU.H)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
High Client EngagementHigh client engagement and positive health outcomes underscore the effectiveness of Newtopia's programs, strengthening client relationships and supporting retention, which are vital for sustained revenue growth and market differentiation.
Negative Factors
Negative Cash FlowNegative cash flow trends suggest Newtopia is not generating sufficient cash from operations, increasing reliance on external funding. This could constrain liquidity and operational flexibility, impacting future growth and sustainability.

Newtopia (NEWU.H) vs. iShares MSCI Canada ETF (EWC)

-5%0%5%10%15%20%25%30%TSE:NEWU.H0.00%EWC+18.88%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 866.33K
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.1
Beta (1Y)
-0.17
Revenue Growth
―
EPS Growth
―
Country
Canada
Employees
100
Sector
General
Sector Strength
55
Industry
Medical - Healthcare Information Services

Newtopia Business Overview & Revenue Model

Company Description

Newtopia Inc., a health technology company, delivers disease prevention solutions. It offers a personalized habit change platform that focuses on physical and mental health risk reduction. The company was incorporated in 2008 and is headquartered in...

How the Company Makes Money

Newtopia makes money primarily through subscription-based revenue models, where clients, including individuals and employers, pay for access to its personalized health improvement programs. The company partners with employers and health insurers who...

Newtopia Earnings Call Summary

Earnings Call Date:Nov 27, 2024(Q3-2024)|Next Earnings Date:Aug 12, 2020
Earnings Call SentimentNeutral

The earnings call highlighted promising strategic partnerships and key client renewals, indicating strong potential for growth and profitability in the future. However, the company faced significant revenue declines and an EBITDA loss this quarter. Despite these challenges, the operational efficiencies and high engagement rates suggest a positive outlook.

Positive Updates

New Strategic Partnership in Supplemental Insurance
Newtopia has entered a strategic partnership with a supplemental insurance payvider to offer their habit change platform to thousands of U.S. workers as a fully covered benefit starting in 2025. This partnership has the potential to significantly accelerate participant acquisition and reach profitability in 2025.

Negative Updates

Revenue Decline
Q3 2024 revenue totaled $1.0 million compared to $2.4 million in the prior year period, driven by the loss of a client and structural incentive changes at an existing client.

Company Guidance

During the Q3 2024 earnings call for Newtopia Inc., key guidance was shared highlighting the company's strategic focus and financial metrics. Newtopia reported a revenue of $1.0 million for Q3 2024, down from $2.4 million in the prior year, primarily due to the loss of a client and structural changes at another existing client. Despite this, the company maintained a gross profit of $0.3 million, equating to 34% of revenue. The company is targeting profitability in 2025, supported by a new strategic partnership with a U.S. payvider to make its habit change platform available to workers at no out-of-pocket cost. Additionally, Newtopia achieved significant client engagement, with one Fortune 10 partner reaching 72% engagement and 30% of their population achieving a clinically significant weight loss. Newtopia aims to leverage these successes to drive growth through strategic partnerships and innovations in health AI, further improving outcomes and reducing costs for its clients.

Newtopia Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TSE:NEWU.H against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TSE:NDATTSE:NDAT45NeutralCAD 1.24M-16.67-49.83%――0.00%
TSE:CHSTSE:CHS42NeutralCAD 9.86M-1.4764.52%―7.63%-106.03%
TSE:UDOCTSE:UDOC41NeutralCAD 4.32M-1.33355.56%―614.03%51.97%
TSE:DMEDTSE:DMED39UnderperformCAD 3.29M-1.61739.84%――-28.35%
TSE:AIDRTSE:AIDR38UnderperformCAD 41.52M-1.52-444.52%―415.06%-54.80%

* General Sector Average

Performance Comparison

0%500%1000%TSE:NEWU.HTSE:NDATTSE:AIDRTSE:CHSTSE:UDOCTSE:DMEDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:NEWU.H and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:NEWU.HNewtopia, Inc.0.010.000.00%
TSE:NDATnDatalyze Corp0.030.01100.00%
TSE:AIDRRocket Doctor Ai Inc0.41-0.37-47.44%
TSE:CHSComprehensive Healthcare Systems Inc0.34-0.16-32.00%
TSE:UDOCUnidoc Health Corp.0.05-0.14-73.68%
TSE:DMEDDiagnaMed Holdings Corp.0.03-0.05-64.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.